Skip to navigation Skip to content

Clinical Trial: Ocrelizumab

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 786
Medication: Ocrelizumab
Location: Colorado
Institutions: Advanced Neurology of CO/Advanced Neurosciences Research
2121 East Harmony Road Suite 180 Fort Collins CO 80528
  Contact Information
Kelley Sage
970-237-9141
kelleys.advancedneurology@gmail.com

Funding:

F. Hoffmann-La Roche Ltd

Description

This is a double blind, multicenter study to evaluate the effectiveness, safety and pharmacokinetics (how the drug moves within the body) of a higher dose of ocrelizumab taken via intravenous infusion every 24 weeks in people with relapsing MS, in comparison to the approved 600 mg dose of ocrelizumab. People will be randomly assigned to receive the higher or approved dose.
 

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.